Breast Cancer Research (Aug 2023)

miR-203 drives breast cancer cell differentiation

  • Nuria G. Martínez-Illescas,
  • Silvia Leal,
  • Patricia González,
  • Osvaldo Graña-Castro,
  • Juan José Muñoz-Oliveira,
  • Alfonso Cortés-Peña,
  • María Gómez-Gil,
  • Zaira Vega,
  • Verónica Neva,
  • Andrea Romero,
  • Miguel Quintela-Fandino,
  • Eva Ciruelos,
  • Consuelo Sanz,
  • Sofía Aragón,
  • Leisy Sotolongo,
  • Sara Jiménez,
  • Eduardo Caleiras,
  • Francisca Mulero,
  • Cristina Sánchez,
  • Marcos Malumbres,
  • María Salazar-Roa

DOI
https://doi.org/10.1186/s13058-023-01690-9
Journal volume & issue
Vol. 25, no. 1
pp. 1 – 21

Abstract

Read online

Abstract A hallmark of many malignant tumors is dedifferentiated (immature) cells bearing slight or no resemblance to the normal cells from which the cancer originated. Tumor dedifferentiated cells exhibit a higher capacity to survive to chemo and radiotherapies and have the ability to incite tumor relapse. Inducing cancer cell differentiation would abolish their self-renewal and invasive capacity and could be combined with the current standard of care, especially in poorly differentiated and aggressive tumors (with worst prognosis). However, differentiation therapy is still in its early stages and the intrinsic complexity of solid tumor heterogeneity demands innovative approaches in order to be efficiently translated into the clinic. We demonstrate here that microRNA 203, a potent driver of differentiation in pluripotent stem cells (ESCs and iPSCs), promotes the differentiation of mammary gland tumor cells. Combining mouse in vivo approaches and both mouse and human-derived tridimensional organoid cultures, we report that miR-203 influences the self-renewal capacity, plasticity and differentiation potential of breast cancer cells and prevents tumor cell growth in vivo. Our work sheds light on differentiation-based antitumor therapies and offers miR-203 as a promising tool for directly confronting the tumor-maintaining and regeneration capability of cancer cells.